Rezera Inc. S-1/Aamended IPO prospectus

Executive Summary

Rezera develops oral anti-inflammatory medicines for patients with cardiovascular and neurological diseases; it has no approved products or drug-sales revenue. Its priority is ruvonoflast for peripheral artery disease, moving toward a pivotal trial despite having no trial results in that patient population. Development spending is accelerating and losses are widening. At the midpoint, the all-primary IPO would raise $200M gross at an implied $249M market capitalization, giving buyers 80% ownership; the investment case requires promising inflammation biomarkers to translate into better patient function and regulatory approval.

Business Model and Growth Drivers

Rezera owns worldwide rights to ruvonoflast and trabzanoflast. Future revenue depends on approval and commercialization, rather than an existing customer business. Management intends to launch ruvonoflast itself in the U.S., initially targeting ≈50 specialist centers, then pursue broader atherosclerotic cardiovascular disease indications.

Both candidates inhibit NLRP3, an upstream driver of inflammation. Ruvonoflast penetrates peripheral tissues and the brain; trabzanoflast emphasizes brain exposure. Ruvonoflast has completed five human trials with generally favorable tolerability, but efficacy evidence is principally biomarker-based. RESOLVE-1 missed its primary weight-loss endpoint; a post-hoc subgroup showed week-four reductions of 56%–63% in high-sensitivity C-reactive protein, an inflammation marker. RESOLVE-2 showed additional inflammation reduction when combined with semaglutide, without additional weight loss. Neither trial establishes benefit in peripheral artery disease.

The proposed RELIEVE-PAD Phase 3 trial would enroll ≈800 patients and assess maximum walking distance after ≈12 months. Management plans initiation in H1 2027, results in 2028 and a drug-approval application in early 2029. Reported regulatory alignment on core design elements is not assurance that one pivotal trial will suffice.

Management estimates a ≈$5B potential ruvonoflast market, dependent on pricing, reimbursement and penetration assumptions. Competition includes NLRP3 programs at Novartis, AstraZeneca, Lilly and Roche. Rezera has only 21 employees, outsources manufacturing and currently depends on one supplier for ruvonoflast drug substance and proprietary material.

The Offering

• The unpriced offering comprises 16,666,667 shares at $11.00–$13.00. Implied gross proceeds are $183M–$217M and market capitalization is $229M–$270M, using 20,776,793 post-offering shares across both classes; buyers receive 80%. Including outstanding options, warrants and quantified IPO executive-option commitments gives 22,112,495 fully diluted shares, $243M–$287M capitalization and 75% buyer ownership, before unquantified grants and unused plan reserves. Revenue and earnings multiples are inapplicable.
• All shares are primary: proceeds go to Rezera, not selling holders. Midpoint net proceeds are ≈$181M, or ≈$209M with the 2,500,000-share, 30-day underwriter option. Jefferies, TD Securities and Cantor lead the offering; Nasdaq listing under RZRA is a closing condition.
• Proceeds principally fund ruvonoflast through Phase 3 topline results and general operations. Management projects runway through Q1 2029, but not through regulatory approval or trabzanoflast Phase 2 topline results.
• GSK has nonbinding interest in up to 2,083,333 offering shares, worth $25.0M at midpoint. Qualifying participation activates negotiation rights over certain ruvonoflast and change-of-control transactions, including exclusive negotiation periods; GSK need not subsequently transact.
• At midpoint, each $12.00 share is backed by $9.52 of net tangible assets after the IPO, a $2.48 gap. Existing holders paid an average $53.81 per share on the filing’s as-converted basis.
• Substantially all existing securities, including management holdings, face 180-day lock-ups, subject to exceptions and early release. Up to 4,110,126 additional shares may subsequently become sale-eligible.

Key Financial Highlights

Historical amounts in $M; losses and outflows in parentheses.

“After IPO” assumes July financing, preferred-stock conversion, specified award and repurchase adjustments, and the midpoint offering.

• Spending concentration: H1 2026 ruvonoflast R&D reached $13.9M from $4.70M, including $7.9M of additional trial-vendor costs and $1.4M of manufacturing-development work.
• Non-operating effects: H1 currency results swung from a $2.00M gain to a $1.45M loss as exchange rates changed the value of intercompany funding; prior-year convertible-note remeasurement losses partly offset that comparison.
• Cash conversion: H1 cash outflow was below net loss partly because accrued R&D and other working-capital timing deferred cash payments.
• Capital bridge: The deficit reflects $211M of accumulated losses and $201M of preferred stock held outside equity—not heavy borrowing. July equity financing and preferred conversion lift equity to $16.8M before IPO proceeds; July financing adds ≈$30.1M cash.
• Liquidity: Without the IPO, July financing extends operations only into January 2027. Further funding remains necessary even if the offering succeeds.

Governance and Control

• Voting common shares carry one vote each; Blue Owl receives non-voting shares subject to a 4.50% voting-ownership cap. Novo’s post-offering voting stake is 4.88%; no disclosed holder controls the company.
• CEO Geoffrey McDonough joined in February 2026 and has contractual options intended to maintain ≈5% fully diluted ownership. Quantified IPO grants to Alan Watt and Nicholas Clarke total 405,085 options, with no intrinsic value at issuance because their exercise price equals the IPO price.
• A five-member, majority-independent board replaces investor-appointed representation. Staggered terms and supermajority removal requirements make rapid board changes harder; new equity plans reserve 3,000,000 shares with potential annual increases.

Risk Assessment

• Audit and controls: The auditor flagged going-concern uncertainty, and transaction-recognition and financial-oversight weaknesses remain under remediation after a fraudulent-wire incident.
• Clinical concentration: Ruvonoflast has never been tested in the target disease; biomarker improvements may not produce walking benefits, and regulators could require more trials.
• Funding dependence: The planned runway does not reach approval, exposing shareholders to further dilution or unfavorable partnerships.
• Supply and exclusivity: Single-source drug supply can delay trials, while limited issued patent protection leaves commercialization vulnerable.
• Key personnel: A small team depends on executives and scientists without key-person insurance; departures could disrupt development.
• Strategic constraints: Conditional GSK negotiation rights could delay or deter competing transactions without guaranteeing a partnership.

What to Watch

• RELIEVE-PAD execution: Watch whether the planned H1 2027 start occurs with the proposed design; delays or additional regulatory requirements weaken the timetable.
• Clinical translation: The company targets 2028 results; improved walking performance with acceptable safety would support the case, while biomarker-only effects would not.
• Funding delivery: Watch whether proceeds carry ruvonoflast through topline results and operations through Q1 2029, rather than requiring an earlier raise or program cuts.